Imnovid (pomalidomide) - Important Safety Information from Celgene Ltd. as approved by the Health Products Regulatory Authority

Notice type: 3rd Party Publications

Date: 30/04/2015

 

Problem Or Issue:
Important safety information communication from Celgene Ltd. to minimise the risk of serious hepatotoxicity, interstitial lung disease and cardiac failure associated with Imnovid (pomalidomide).
 
Important Safety Information - Imnovid (pomalidomide)



« Back